Chikungunya Virus Vaccine Candidates with Decreased Mutational Robustness Are AttenuatedIn Vivoand Have Compromised Transmissibility
Abstract
Chikungunya fever is a debilitating disease that causes severe pain to the joints, which can compromise the patient’s lifestyle for several months and even in some grave cases lead to death. The etiological agent is chikungunya virus, an alphavirus transmitted by mosquito bite. Currently, there are no approved vaccines or treatments against the disease. In our research, we developed novel live attenuated vaccine candidates against chikungunya virus by applying an innovative genomic design. When tested in the insect and mammalian host, the vaccine candidates did not cause disease, elicited strong protection against further infection, and had low risk of reversion to pathogenic phenotypes.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Sep 15, 2019
- Source ID
- 10.1128/jvi.00775-19
Entities
People
- Daniela Megrian
- Gonzalo Moratorio
- Herve Blanc
- James Weger-Lucarelli
- Kenneth A. Stapleford
- Laura I Levi
- Lucia Carrau
- Marco Vignuzzi
- María G. Noval
- Veronica V. Rezelj
Organizations
- Grossman School of Medicine
- Pasteur Institute
- Pasteur Institute of Montevideo
- University of the Republic
- Virginia Tech